Natera reports USD 752.75 million Q2 revenue. Natera stock faces November 5 results

Published on 10/27/2026 at 18:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 net loss was USD 66.97 million, with diluted EPS of USD -0.47. Natera stock costs EUR 368.95 on October 27, 2026 at 6:01 p.m. CEST.

Reporting date and growth

Natera reported USD 752.75 million in second-quarter revenue on August 6, 2026.
Second-quarter net loss was USD 66.97 million, with diluted earnings per share of USD -0.47.
Natera stock costs EUR 368.95 at Lang & Schwarz on October 27, 2026 at 6:01 p.m. CEST.
MarketBeat lists November 5, 2026 for the third-quarter results announcement.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) reported USD 752.75 million in second-quarter revenue for the period ended June 30, 2026, while its net loss reached USD 66.97 million. MarketBeat lists November 5, 2026 as the estimated date for the company's third-quarter results. The stock was trading at EUR 368.95 at Lang & Schwarz on October 27, 2026 at 6:01 p.m. CEST.

Revenue growth meets a loss

The second-quarter revenue figure represented growth of 37.70 percent from the prior-year period, according to MarketBeat. Diluted earnings per share came to USD -0.47, compared with the source's consensus estimate of USD -0.4939 for the quarter. The comparison shows stronger per-share performance than expected even as Natera remained loss-making.

Natera's investor-relations page describes the company as a cell-free DNA testing specialist serving women's health, oncology, and organ health. Its named products include Panorama, Signatera, and Prospera, while the company says its technology has been supported by more than 400 peer-reviewed publications and more than 70,000 annual patient and provider support sessions, according to Natera.

November 5 date sets the next test

The next scheduled catalyst is the third-quarter announcement listed for November 5, 2026, after the market close, with a conference call scheduled for 4:30 p.m. ET. MarketBeat gives a consensus revenue estimate of USD 707.54 million and consensus diluted earnings per share of USD -0.2812 for that quarter. Those estimates would put revenue below the second-quarter result of USD 752.75 million while narrowing the expected per-share loss.

Valuation and market position

Natera's latest quote data show a USD 59.4 billion market capitalization, a 52-week range of USD 181.00 to USD 437.41, and a Nasdaq listing under the ticker NTRA, all as of October 27, 2026. The primary-market quote was USD 411.96 at 5:04 p.m. UTC on October 27, 2026, while the German euro quotation was EUR 368.95 later that evening.

The company operates in healthcare and medical diagnostics and research. The combination of 37.70 percent second-quarter revenue growth, a USD 66.97 million quarterly net loss, and the November 5 reporting date gives investors three concrete markers for the next update.

Stock stays tied to the next report

Natera's second-quarter revenue growth remains the strongest operating figure ahead of the November announcement, while the negative earnings result keeps profitability central to the next report. The stock was trading at EUR 368.95 at Lang & Schwarz on October 27, 2026 at 6:01 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Natera stock.